Abbas Assesses the Use of Allogenic Transplant In MPNsMarch 23rd 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan Abbas, MD, discussed with his fellow clinicians the use of allogeneic hematopoietic stem cell transplant in patients with myeloproliferative neoplasms and how ruxolitinib fits into their care.
ASCT Shows No OS Effects vs Maintenance Rituximab After BR or R-CHOP in MCLMarch 23rd 2023
Clinical trials exploring regimens without ASCT consolidation in young patients with MCL are needed, and maintenance with rituximab should be considered for patients after first-line treatment with bendamustine plus rituximab and R-CHOP
Roundtable Discussion: Krishnan Debates the Rationale For Various Therapies in Multiple MyelomaMarch 23rd 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Amrita Krishnan, MD, discussed with participants their choice of therapy for a patient with multiple myeloma who relapsed after receiving bortezomib, lenalidomide, and dexamethasone followed by autologous stem cell transplant and 2 years of lenalidomide maintenance.
Zolbetuximab/CAPOX Prolongs Survival in CLDN18.2-Positive/HER2-Negative Advanced Gastric/GEJ CancersMarch 22nd 2023
FDA approval may be looming for the combination of zolbetuximab and capecitabine/oxaliplatin after primary phase 3 results were presented during the March ASCO Virtual Plenary.
Updates on Recent Advances and Treatments for Hematologic MalignanciesMarch 22nd 2023
In an interview with Targeted Oncology, Guenther Koehne, MD, PhD, provided an overview of The Summit of Americas on Immunotherapies for Hematologic Malignancies and some of the recent and exciting advances being seen in the hematology space.
ISB 1442 Lands FDA Orphan Drug Status for R/R Multiple MyelomaMarch 22nd 2023
ISB 1442, a 2+1 biparatopic bispecific antibody that has CD38 and CD47 targeting domains, has received an orphan drug designation from the FDA and is being assessed in a phase 1/2 clinical trial for patients with multiple myeloma.
Dosing and Management: Optimal Use of Tafasitamab/Lenalidomide for Relapsed DLBCLMarch 22nd 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Bruce D. Cheson, MD, discussed adverse event management and dosing strategies for patients receiving tafasitamab and lenalidomide for diffuse large B-cell lymphoma.
Teclistamab Provides a Superior Response for Patients with R/R Multiple MyelomaMarch 21st 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Rafael Fonseca, MD, discusses the efficacy and safety with teclistamab for patients with relapsed/refractory multiple myeloma.
CARTITUDE-1 Update: Cilta-Cel Maintains Benefit in R/R Multiple MyelomaMarch 21st 2023
At a prespecified analysis of the CARTITUDE-1 trial with a median follow-up of approximately 28 months, treatment with cilta-cel continued to elicit positive responses and maintained a favorable risk/benefit profile for patients with multiple myeloma.
Oh Explores Current JAK Inhibitor Options for Primary MyelofibrosisMarch 21st 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Stephen Oh, MD, discussed treatment options for steroid-refractory high-risk primary myelofibrosis based on the patient's platelet count.
Expert Marks Anti-VISTA/Anti-PD-1 Therapies as a Potential New Strategy for Advanced Solid TumorsMarch 20th 2023
Anti-VISTA therapy may be the therapy type to be used with PD-1/PD-L1 inhibitors to treat patients with advanced solid tumors, expert say. One agent, KVA12123, has just entered phase 1 clinical research.
Patritumab Deruxtecan Elicits Clinical Activity in Some Patients With Lung and Breast CancerMarch 20th 2023
Two studies of patritumab deruxtecan in patients with EGFR-mutated metastatic non–small cell lung cancer and HER3-expressing metastatic breast cancer revealed promising overall response, disease control, progression-free survival rates, and more.
Leveraging ctDNA to Predict Response in Patients With Myeloma Receiving CAR T CellsMarch 20th 2023
In an interview with Targeted Oncology, Hitomi Hosoya, MD, discussed the potential use of ctDNA in the myeloma space, including its ability to sequence BCMA-targeted therapies and reduce the need for bone marrow exams.